The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance_West China Medical Journal

Authors：

ZHONG Li ¹ , CHEN Qiu ² , YANG Tingqiang ³

1. Department of Endocrinology and Metabolism, the First People’s Hospital of Longquanyi District, Chengdu, Sichuan 610100, P. R. China; 2. Department of Endocrinology, University of Chinese Traditional Medicine, Chengdu, Sichuan 611130, P. R. China; 3. Department of Endocrinology, the People’s Hospital of Xinjin, Xinjin, Sichuan 611400, R. R. China;

Corresponding?author：

Keywords：

Grave病; 白細胞介素-2; 白細胞介素-12p40; 自身免疫

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探討Grave病患者采用131I治療前后血清中白細胞介素-2（IL-2）及白細胞介素-12 p40（IL-12p40）含量的改變及細胞因子在該疾病中的作用與意義。方法　采用酶聯免疫吸附試驗雙抗夾心法、放射免疫法，對2009年10月－2011年12月收治的28例Grave病患者（治療組）經131I治療前后血清中IL-2和IL-12p40含量進行自身對比及與健康志愿者（對照組）對比；同時對治療組患者治療前、后的血清游離三碘甲腺原氨酸（FT3）、血清游離甲狀腺素（FT4）、促甲狀腺激素（TSH）水平與對照組進行對比。結果　治療后患者血清中IL-2和IL-12p40的水平為（19.54 ± 11.17）、（615.88 ± 349.32） ng/mL，明顯高于治療前（P＜0.05），且與對照組比較差異無統計學意義（P＞0.05）；患者治療前后血清中IL-2和IL-12p40水平與FT3、FT4水平有顯著相關性。結論　血清IL-2和
IL-12p40可能共同參與Grave病的發病過程，并且這兩種因子的水平與FT3、FT4水平呈負相關性。

Citation： ZHONG Li,CHEN Qiu,YANG Tingqiang. The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance. West China Medical Journal, 2012, 27(9): 1335-1337. doi: Copy

1.	Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
2.	Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
3.	Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
4.	楊吉生, 薛蘭芳, 胡明造, 等. Graves病碘-131治療的劑量計算[J]. 云南醫藥, 1996, 17(1): 2-4.
5.	楊吉生, 王強, 胡明造, 等. 131I治療Graves病的最適劑量探討[J]. 同位素, 2000, 12(3): 177-181.
6.	Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
7.	InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
8.	Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
9.	池沛冬, 李麗, 范艷瑩, 等. IL-12恢復并促進氟尿嘧啶抑制的T細胞免疫功能[J]. 癌癥, 2007, 26(8): 801-808.
10.	謝建平, 吳成秀, 嚴宗遜, 等. Graves病治療前后細胞因子水平的變化[J]. 中華核醫學雜志, 2004, 24(4): 247-249.
11.	朱明風, 溫赤君, 錢紅. 131I治療Graves病的轉歸與三種細胞因子的關系[J].標記免疫分析與臨床, 2007, 14(3): 150-152.
12.	ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
13.	Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
14.	InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
15.	梁馳, 何鳳屏, 曾建業, 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的變化[J]. 廣西醫學, 2008, 30(8): 1146-1147.
16.	何長武, 黃鶯, 王社教. 甲亢患者131碘治療前后細胞因子水平的變化分析[J]. 陜西醫學雜志, 2011, 40(11): 1493-1494.
17.	湯建林, 李玉瑩, 高柳艷, 等. 131I治療Graves病療效評價[J]. 醫學理論與實踐, 2011, 24(13): 1551-1552.
18.	李春北. IL-2與IL-10濃度變化對Graves病治療效果的預測[J]. 重慶醫科大學學報, 2010, 3(3): 412-414.

1. 　Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
2. 　Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
3. 　Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
4. 　楊吉生, 薛蘭芳, 胡明造, 等. Graves病碘-131治療的劑量計算[J]. 云南醫藥, 1996, 17(1): 2-4.
5. 　楊吉生, 王強, 胡明造, 等. 131I治療Graves病的最適劑量探討[J]. 同位素, 2000, 12(3): 177-181.
6. 　Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
7. 　InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
8. 　Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
9. 　池沛冬, 李麗, 范艷瑩, 等. IL-12恢復并促進氟尿嘧啶抑制的T細胞免疫功能[J]. 癌癥, 2007, 26(8): 801-808.
10. 　謝建平, 吳成秀, 嚴宗遜, 等. Graves病治療前后細胞因子水平的變化[J]. 中華核醫學雜志, 2004, 24(4): 247-249.
11. 　朱明風, 溫赤君, 錢紅. 131I治療Graves病的轉歸與三種細胞因子的關系[J].標記免疫分析與臨床, 2007, 14(3): 150-152.
12. 　ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
13. 　Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
14. 　InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
15. 　梁馳, 何鳳屏, 曾建業, 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的變化[J]. 廣西醫學, 2008, 30(8): 1146-1147.
16. 　何長武, 黃鶯, 王社教. 甲亢患者131碘治療前后細胞因子水平的變化分析[J]. 陜西醫學雜志, 2011, 40(11): 1493-1494.
17. 　湯建林, 李玉瑩, 高柳艷, 等. 131I治療Graves病療效評價[J]. 醫學理論與實踐, 2011, 24(13): 1551-1552.
18. 　李春北. IL-2與IL-10濃度變化對Graves病治療效果的預測[J]. 重慶醫科大學學報, 2010, 3(3): 412-414.

West China Medical Journal

The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance

Abstract Full text Figures/Tables Video References Cited by

Format

Content